<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Resistin-like molecule beta (RELMbeta), an intestinal goblet cell-specific protein, is a biomarker of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and over-expressed in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Since <z:mp ids='MP_0008010'>gastric adenocarcinomas</z:mp> can arise through a process of intestinalization, we hypothesized that RELMbeta might be aberrantly expressed in <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This study was undertaken to examine the RELMbeta expression in <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> and correlate it with clinical outcome </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred and thirty-six <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> patients were evaluated for the RELMbeta expression by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>The RELMbeta transcripts were measured by real-time quantitative PCR </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> gastric mucosa, RELMbeta expression was absent, whereas areas of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> revealed RELMbeta reactivity </plain></SENT>
<SENT sid="6" pm="."><plain>Eighty-nine patients of <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> (65.4%) were positive for RELMbeta expression </plain></SENT>
<SENT sid="7" pm="."><plain>In a subtotal of 20 patients, RELMbeta transcripts were positively correlated with protein levels in <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> tissues, but absent in <z:mpath ids='MPATH_458'>normal</z:mpath> gastric mucosa </plain></SENT>
<SENT sid="8" pm="."><plain>The expression rate of RELMbeta was higher in intestinal-type <z:mp ids='MP_0002038'>carcinomas</z:mp> than in diffuse-type <z:mp ids='MP_0002038'>carcinomas</z:mp> (P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>RELMbeta positivity in <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> was positively correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation (P = 0.001) and inversely correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration (P = 0.007), lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = 0.035), and heparanase expression (P &lt; 0.001), without correlation with age, gender, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location and size, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> stages, and Ki-67 expression </plain></SENT>
<SENT sid="10" pm="."><plain>Patients showing positive RELMbeta expression had a significantly longer overall survival than those with negative expression (P = 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>These results provide evidences that the RELMbeta expression in <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> is correlated with clinicopathological features and may be a useful prognostic factor for predicting the outcome of <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> patients </plain></SENT>
</text></document>